566P Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
| Autor: | Liam, C.K., Kim, T.M., Yang, J-J., Huang, C., Voon, P-J., Tho, L.M., Zhou, Q., Wang, J., Hayashi, H., Tan, D.S.W., Danchaivijitr, P., Nguyen, V.N., Wong, K.H., Yang, J.C-H., Le, X., Ellers-Lenz, B., Karachaliou, N., Ghori, V., Berghoff, K., Wu, Y-L. |
|---|---|
| Zdroj: | In Annals of Oncology November 2023 34 Supplement 4:S1691-S1691 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|